Adefovir indications and usage: Difference between revisions
(Created page with "__NOTOC__ {{Adefovir}} {{CMG}} ==Indications And Usage== HEPSERA is indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of ...") |
No edit summary |
||
| Line 4: | Line 4: | ||
==Indications And Usage== | ==Indications And Usage== | ||
HEPSERA is indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. | HEPSERA is indicated for the treatment of chronic [[hepatitis]] B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. | ||
This indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function. | This indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic [[hepatitis]] B with compensated liver function, and with clinical evidence of lamivudine-resistant [[hepatitis]] B virus with either compensated or decompensated liver function. | ||
For patients 12 to less than 18 years of age, the indication is based on virological and biochemical responses in patients with HBeAg+ chronic hepatitis B virus infection with compensated liver function.<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021449s020lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021449s020lbl.pdf | publisher = |date = | accessdate = }}</ref> | For patients 12 to less than 18 years of age, the indication is based on virological and biochemical responses in patients with HBeAg+ chronic [[hepatitis]] B virus infection with compensated liver function.<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021449s020lbl.pdf | url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021449s020lbl.pdf | publisher = |date = | accessdate = }}</ref> | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Latest revision as of 01:39, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Indications And Usage
HEPSERA is indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease.
This indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function.
For patients 12 to less than 18 years of age, the indication is based on virological and biochemical responses in patients with HBeAg+ chronic hepatitis B virus infection with compensated liver function.[1]
References
- ↑ "http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021449s020lbl.pdf" (PDF). External link in
|title=(help)
Adapted from the FDA Package Insert.